Clinical trials: Breast Neoplasms, completed
Lymphedema Arm
Extracellular Fluid Changes During Neoadjuvant Chemotherapy
The purpose of this prospective clinical study is to evaluate whether neoadjuvant chemotherapy (NACT) is associated with an increase in extravascular (extracellular) fluid in the ipsilateral upper extremity, an early indicator of…
- Trial name
- NCT07315880
- Where
- Turkey (Türkiye)
- Volunteers
- 111 people
- Sponsor
- Florence Nightingale Hospital, Istanbul
Advanced Triple-Negative Breast Cancer
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast…
- Trial name
- NCT06685796
- Testing
- BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- BeBetter Med Inc
Breast Cancer
Combination Chemotherapy in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003088
- Testing
- cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Where
- 19 sites in United States, Canada
- Volunteers
- 2,005 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia
OVArian Cancer Non-Interventional Study - OVATAR
This is a multicentre, non-interventional, prospective study to be carried out in representative hospitals in order to assess 1st line treatment management and diagnostic approaches applied to ovarian, peritoneal and fallopian…
- Trial name
- OVATAR (NCT02122588)
- Where
- 22 sites in Russia
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Recurrent Breast Cancer, Stage IV Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase II trial to study the effectiveness of combination chemotherapy with or without trastuzumab in treating women who have metastatic breast cancer.
- Trial name
- NCT00004888
- Testing
- pegylated liposomal doxorubicin hydrochloride, docetaxel, trastuzumab
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer.
ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.
The purpose of this study is to determine if NIF fluoresent imaging is an effctive approch to detect the margine of the breast tumoral tissue.
- Trial name
- EC2075 (NCT01993576)
- Testing
- Indocyanine Green
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Jules Bordet Institute
Healthy Participants
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
This study will assess the effect of multiple doses of AZD5462 on the PK of oral midazolam (CYP3A4 probe), rosuvastatin (OATP1B1/3, BCRP probe), and digoxin (P-gp probe) in healthy participants.
- Trial name
- NCT05395117
- Testing
- AZD5462, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Breast Cancer
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00373191
- Testing
- chemotherapy, endocrine therapy, DNA methylation analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasm Malignant Female
Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients
PRO-COM Project: Randomized-controlled study evaluating the impact of electronic patient reported outcome (ePRO) surveys on patient-physician communication and quality of life in patients with advanced breast cancer
- Trial name
- NCT03525990
- Testing
- Questionnaires
- Where
- 2 sites in Austria
- Volunteers
- 62 people
- Sponsor
- Dr. Vera Trommet
Metastatic Breast Cancer
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer
- Trial name
- NCT00319618
- Testing
- Gefitinib, Docetaxel
- Where
- Norway
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Breast Cancer
Acupuncture for Aromatase Inhibitor Induced Joint Pain
This is a randomized, controlled, pilot study to determine the safety and efficacy of acupuncture as an adjunct to pharmacological treatment compared to pharmacological intervention alone for the treatment of musculoskeletal pain…
- Trial name
- NCT00826397
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Breast Cancer
Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints
The aim of the proposed study is to investigate whether women treated for breast cancer who experience cognitive difficulties will profit from the Internet-based program Scientific Brain Training Pro with respect to: 1)…
- Trial name
- NCT01866813
- Testing
- Cognitive training intervention group
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- University of Aarhus
Breast Cancer
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
The purpose of this research study is to : Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER negative (estrogen-receptor-negative), PR negative (progesterone receptor-negative), HER2 negative…
- Trial name
- NCT00483223
- Testing
- Cisplatin, carboplatin
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and…
- Trial name
- NCT01186991
- Testing
- Onartuzumab, Bevacizumab, Paclitaxel
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 185 people
- Sponsor
- Genentech, Inc.
Metastatic Breast Cancer, Solid Tumors
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.
- Trial name
- NCT02719691
- Testing
- Alisertib, MLN0128
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by…
- Trial name
- NCT00875979
- Testing
- Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
- Where
- 20 sites in United States, Belgium and 5 more
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: The timing of breast cancer surgery within the menstrual cycle may affect outcome. It is not yet known if treatment is more effective during the initial or final phase of the menstrual cycle.
- Trial name
- NCT00005079
- Testing
- conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Survivorship, Cognitive Dysfunction
Biobehavioral Correlates of Cancer-related Cognitive Dysfunction and Its Co-occurring Symptoms
This descriptive, cross-sectional study will evaulate and fully characterize factors associated with cognitive dysfunction in Breast Cancer (BCS) and Colorectal Cancer (CRC) survivors that have cognitive concerns, and factors…
- Conditions
- Survivorship, Cognitive Dysfunction, Pain, Depression
- Trial name
- NCT04611620
- Testing
- Cognitive Dysfunction
- Where
- United States
- Volunteers
- 682 people
- Sponsor
- Indiana University
Breast Cancer Female
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 \& day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4 cycles is the standard clinical…
- Trial name
- NCT03381417
- Testing
- pegcyte, Neulastim
- Where
- Vietnam
- Volunteers
- 128 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.